Ipca Labs Q1FY27: Revenue Guidance Raised, Margins Improve on Strong Growth
Ipca Laboratories Ltd 路 Transcript 路 17 Aug 2026, 5:29 pm
Ipca Labs Q1FY27: Revenue Guidance Raised, Margins Improve on Strong Growth Ipca Labs reported strong Q1FY27 results, with consolidated revenue up 21% YoY to INR 2,788 crores. Consolidated EBITDA margin improved significantly to 22.88% from 18.39% in Q1FY26, driven by operating leverage. Domestic formulations grew 13%, exports 34%, and APIs 30%. Citing strong performance, management raised full-year FY27 revenue growth guidance to 14-16% from 12-13% previously. FY27 consolidated EBITDA margin guidance was also revised upwards to ~23% from 22%. Capex is guided at INR 700-800 crores for the year.
Original exchange filing (PDF)
More announcements from Ipca Laboratories Ltd
- Transcript of Conference Call held on 05.11.2026 路 06 Nov 2026
- Audio Link of Conference Call held on 05.11.2026 路 05 Nov 2026
- Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026 路 05 Nov 2026
- Standalone and Consolidated Financial Results for second quarter and half year ended 30.09.2026 路 05 Nov 2026
- Schedule of Conference Call 路 05 Nov 2026
- To consider and approve the financial results for the period ended September 30, 2026 路 05 Nov 2026
- Ipca Laboratories Limited has informed the Exchange about Board Meeting to be held on 05-Nov-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . 路 05 Nov 2026
- Ipca Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Standalone and Consolidated .... 路 05 Nov 2026
